Modeling Breast Cancer in Human Breast Tissue using a Microphysiological System
April 23rd, 2021
3.9K views
This protocol describes the construction of an in vitro microphysiological system for studying breast cancer using primary human breast tissue with off the shelf materials.
Overview
This protocol describes the construction of an in vitro microphysiological system for studying breast cancer using primary human breast tissue with off the shelf materials. This technique allows for the maintenance of human breast tissue alive ex vivo, facilitating the study of interactions with breast cancer.
Key Study Components
Area of Science
- Breast cancer research
- Microphysiological systems
- Ex vivo tissue maintenance
Background
- This is the first protocol enabling prolonged ex vivo maintenance of human breast tissue.
- The technique preserves various components of breast tissue, including adipocytes and immune cells.
- It has significant implications for personalized medicine and pharmaceutical development.
- Understanding tumor initiation and processes like fibrosis is enhanced through this method.
Purpose of Study
- To enable the study of human breast tissue interactions with breast cancer.
- To develop a system that maintains tissue viability for research.
- To advance knowledge in breast cancer pathophysiology.
Methods Used
- Preparation of a gelatin solution for tissue maintenance.
- Dispensing the solution into wells of a six-well plate.
- Maintaining tissue at 37 degrees Celsius for optimal conditions.
- Utilizing primary human breast tissue for experimental setups.
Main Results
- The protocol successfully maintains human breast tissue alive ex vivo.
- Interactions between breast tissue and cancer can be studied effectively.
- The technique preserves the integrity of tissue structures.
- It opens avenues for research in tumor biology and treatment strategies.
Conclusions
- This protocol represents a significant advancement in breast cancer research methodologies.
- It allows for detailed studies of tissue-cancer interactions.
- The approach can lead to improved understanding and treatment of breast cancer.
Frequently Asked Questions
What is the main advantage of this protocol?
The main advantage is the ability to maintain human breast tissue alive ex vivo, allowing for direct study of its interactions with breast cancer.
How does this technique impact breast cancer research?
It has major implications for personalized medicine, pharmaceutical development, and understanding tumor initiation and progression.
What components of breast tissue are preserved?
The protocol preserves breast adipocytes, immune cells, vascular structures, ductal structures, and extracellular matrix.
Who demonstrated this procedure?
Katherine Hebert and Rakesh Gurrala from Tulane University demonstrated the procedure.
What temperature is required for the gelatin solution?
The gelatin solution needs to be melted in a 37 degrees Celsius water bath.
What is the purpose of the six-well plate in this protocol?
The six-well plate is used to hold the gelatin solution and maintain the breast tissue for experimentation.
Executive Industry Relevance
This microphysiological system addresses a critical gap in breast cancer drug development by enabling prolonged ex vivo culture of primary human breast tissue with native microenvironment components. The model supports mechanistic de-risking of therapeutic candidates through direct observation of tumor-stroma interactions in a human-relevant system. By preserving adipocytes, immune cells, fibroblasts, and extracellular matrix, it improves predictive confidence in preclinical evaluation and reduces reliance on poorly translatable 2D or murine models.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tumor microenvironment interactions using primary human breast tissue with native adipocytes, stromal cells, and immune cells.
- Operational Value: Supports functional target validation by modeling BC motility and metabolic crosstalk in a human-relevant context.
- Predictive Value: Enhances target confidence by demonstrating lipid accumulation and amoeboid movement of cancer cells under physiological conditions.
Screening & Assay Development
- Scientific Value: Provides a stable, reproducible platform for high-resolution time-lapse imaging of cancer cell behavior over 14 days.
- Operational Value: Standardizes tissue preparation and ASC sheet sandwiching for consistent microenvironment recreation across experiments.
- Assay Readiness: Enables quantitative readouts such as lipid droplet formation and cell motility for compound screening.
Translational & Preclinical Research
- Translational Relevance: Uses primary human mammary adipocytes and breast cancer cells to model metabolic crosstalk not seen in murine adipocyte co-cultures.
- Preclinical Continuity: Maintains tissue viability for 14 days, supporting longitudinal studies of tumor initiation, fibrosis, and extracellular matrix remodeling.
- Risk-Adjusted Decisions: Allows comparison of cancer cell responses to chemotherapy in tissue-native vs. 2D culture conditions.
Pipeline & Workflow Integration
The BC-MPS fits within the discovery continuum from target validation through preclinical assessment, offering a human-relevant bridge between in vitro models and in vivo studies.
- Discovery Biology: Supports hypothesis testing of tumor-stroma interactions by preserving native breast tissue architecture and cellular composition.
- Screening: Enables assay standardization through reproducible tissue mincing, ASC sheet formation, and gelatin-based anchorage.
- Analytics: Facilitates quantitative measurements via fluorescence microscopy, flow cytometry, and lipid staining to compare experimental conditions.
- Translational Research: Connects discovery to preclinical work by modeling human-specific metabolic crosstalk and tissue remodeling processes.
- Enterprise Reuse: Establishes a reusable platform for studying breast cancer pathophysiology and drug response in a standardized microenvironment.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence by modeling human breast cancer-stroma interactions with preserved native extracellular matrix and cellular heterogeneity.
- Operational Value: Ensures reproducibility through standardized tissue preparation, ASC sheet integration, and environmental controls (37°C, 5% CO₂).
- Strategic Value: Improves go/no-go decisions by revealing differential drug responses in tissue-native versus 2D culture systems.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on their effects in a complex, human-relevant microenvironment.
Implementation Considerations
- Requires expertise in primary tissue handling, sterile technique, and microphysiological system assembly.
- Dependent on access to fresh human breast tissue, adipose-derived stem cells, and cancer cell lines.
- Necessitates instrumentation for fluorescence microscopy, flow cytometry, and tissue dissociation.
- Involves optimization steps for tissue mincing and gelatin anchorage to prevent buoyancy-related detachment.
- Limited by tissue availability and viability window, requiring coordinated logistics for timely processing.
Biopharma FAQs
Why is null hypothesis testing important for validating BC-MPS models?
Null hypothesis testing ensures observed changes in cancer cell behavior, such as increased motility or lipid accumulation, are statistically significant and not due to random variation. This supports reliable interpretation of microenvironment effects in preclinical studies.
How does isolating independent variables like cancer cell type or tissue source improve discovery pipeline reliability?
Isolating independent variables allows researchers to attribute changes in outcomes—such as lipid droplet formation—to specific factors like cancer cell line or tissue donor, improving reproducibility and target validation confidence.
What quantitative dependent variable measurements enable assessment of BC-MPS functionality?
Quantitative measurements include the proportion of lipid-positive cancer cells (26.2-fold increase vs. 2D), motility metrics from time-lapse imaging, and flow cytometry-based cell sorting efficiency, all providing objective functional readouts.
Why are replication requirements critical for cross-functional collaboration in BC-MPS studies?
Replication ensures that observations like stable tissue anchoring for 14 days or macrophage preservation are consistent across experiments, enabling trusted data sharing between discovery, toxicology, and translational teams.
What statistical analysis capabilities are required before implementing BC-MPS in drug screening workflows?
Implementation requires ability to perform fold-change calculations (e.g., lipid accumulation), compare imaging-based motility metrics, and validate flow cytometry sorting purity to ensure data integrity in screening campaigns.
